Jacobs Levy Equity Management’s Ocular Therapeutix OCUL Stock Holding History

Jacobs Levy Equity Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.98M	Buy	470,029 +176,766	+60%	+$1.68M	0.02%	464
2025 Q4	$3.56M	Buy	+293,263	New	+$3.56M	0.01%	475
2022 Q4	–	Sell	-100,809	Closed	-$418K	–	1007
2022 Q3	$418K	Buy	+100,809	New	+$508K	﹤0.01%	846
2022 Q1	–	Sell	-59,810	Closed	-$417K	–	1055
2021 Q4	$417K	Buy	+59,810	New	+$464K	﹤0.01%	855

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Jacobs Levy Equity Management's OCUL Position: Q1 2026 in Review

Jacobs Levy Equity Management increased its Ocular Therapeutix (OCUL) stake by 60% in Q1 2026, buying an estimated $1.68M and bringing the position to 470,029 shares worth $3.98M. The position accounts for 0.02% of the portfolio, ranked #464.

Jacobs Levy Equity Management first reported a position in OCUL in Q4 2021 and has held it in 4 quarters since. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

Jacobs Levy Equity Management held 470,029 shares of Ocular Therapeutix worth $3.98M as of Q1 2026.
Jacobs Levy Equity Management bought 176,766 Ocular Therapeutix shares in Q1 2026, an estimated $1.68M.
Ocular Therapeutix made up 0.02% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #464 holding.
Jacobs Levy Equity Management first reported a position in Ocular Therapeutix in Q4 2021 and has held it in 4 quarters since.
269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.